

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	)	
Emmanuel Conseiller et al.	)	Group Art Unit: To Be Assigned
	)	
Application Number: To Be Assigned	)	Examiner: To Be Assigned
	)	
Filed: April 11, 2001	)	
	)	
For: POLYPEPTIDES CAPABLE OF INTERACTING WITH ONCOGENIC MUTANTS OF THE p53 PROTEIN	)	

PRELIMINARY AMENDMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination on the merits, please amend this application.

IN THE SPECIFICATION:

On page 1, before line 1, INSERT the following paragraph:

--This application claims priority to international PCT application PCT/FR99/02465, filed October 12, 1999, and priority to prior U.S. provisional application 60/132,331, filed May 3, 1999, and priority to French application FR 98/12754 filed October 12, 1998, each of which are specifically incorporated herein by reference to the full extent allowed. --

IN THE CLAIMS:

Please CANCEL claims 1-30 and INSERT new claims 31-97, as follows.

--31. A polypeptide capable of interacting specifically with oncogenic forms of p53, and capable of stimulating cell growth, and capable of blocking the antiproliferative effects of the wild-type form of p53.

**BEST AVAILABLE COPY**